Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical Inc (RMTI) delivers innovative therapies for chronic kidney disease and hemodialysis patients, including the only FDA-approved iron replacement therapy administered via dialysate. This page provides investors and healthcare professionals with centralized access to official press releases, clinical trial updates, and business developments directly impacting renal care innovation.
Track RMTI's progress in advancing dialysis solutions like triferic® and critical concentrates that maintain metabolic balance during treatment. Stay informed about regulatory milestones, partnership announcements, and research breakthroughs that shape the company's role in improving patient outcomes.
Key updates across three focus areas: iron deficiency management advancements, dialysis product innovations, and strategic initiatives enhancing renal care delivery. Bookmark this resource for verified information on RMTI's contributions to reducing treatment complications in ESRD patients.
Rockwell Medical (Nasdaq: RMTI) reported third quarter 2025 results on November 12, 2025. Q3 net sales were $15.9M, flat sequentially and down 44% year-over-year after the company's largest customer transitioned to another supplier. The company achieved Adjusted EBITDA of $0.05M in Q3 and reported a net loss of $1.8M for the quarter. Cash, cash equivalents and investments increased to $23.7M at September 30, 2025, up $5.3M from June 30 driven by ATM equity issuances partially offset by the Evoqua asset acquisition.
Rockwell reiterated 2025 guidance: net sales $65.0M–$70.0M, gross margin 16%–18%, and Adjusted EBITDA ($0.5M)–$0.5M. Operating actions included restructuring and new long‑term customer agreements, plus a COO promotion.
Rockwell Medical (Nasdaq: RMTI) announced on November 11, 2025 that Rashad Brown joined as Vice President, Manufacturing and Supply Chain. Brown brings more than two decades of manufacturing and supply chain leadership across Abbott, Fresenius Medical Care, and Hearing Lab Technology, with experience in regulated FDA environments, lean manufacturing, automation to boost overall equipment effectiveness, and supplier negotiation.
The company said Brown will focus on scaling the manufacturing footprint, operational efficiency, reliability for dialysis customers, and supplier performance to support near-term development and long-term growth.
Rockwell Medical (Nasdaq: RMTI) will exhibit its hemodialysis concentrates portfolio at ASN Kidney Week 2025, November 6-9, at the George R. Brown Convention Center in Houston, Booth #316.
On display are liquid and dry acid concentrates (CitraPure, Dri-Sate, RenalPure), bicarbonate concentrates (RenalPure, SteriLyte), a 510(k)-approved single-use bicarbonate cartridge (720g and 900g), the Dry Acid Concentrate Mixer, and accessories including cleaners and salt pellets. The dry products enable on-site mixing with reduced storage, lower cost per treatment, and fewer deliveries. More product details are available on the company website.
Rockwell Medical (Nasdaq: RMTI) announced on October 23, 2025 that it was named to the 2025 Fortune Best Workplaces in Manufacturing & Production list in the small & medium category for the second consecutive year.
The recognition is based on employee feedback about management, colleagues, and company values. Rockwell highlighted an improved ranking year-over-year and quoted Lesley Spriggs, Vice President of Human Resources, praising the company culture built on respect, collaboration, inclusivity, and shared purpose.
The announcement emphasizes employee sentiment and the company’s ongoing focus on workplace culture; no financial data or commercial transactions were disclosed.
Rockwell Medical (Nasdaq: RMTI) will release third quarter 2025 financial and operational results for the period ended September 30, 2025 on Wednesday, November 12, 2025. The company will issue a press release at 6:00 AM ET followed by a live conference call and webcast at 8:00 AM ET.
Conference call details: live US dial-in (888) 660-6347, international 1 (929) 201-6594, conference ID 4944610. Webcast and replay available at www.RockwellMed.com/Results. Speakers include Mark Strobeck, Ph.D. (CEO) and Jesse Neri (SVP, CFO).
Rockwell Medical (Nasdaq: RMTI) has promoted Heather Hunter to the position of Chief Operating Officer. Hunter, who joined the company in August 2022 as SVP, Chief Corporate Affairs Officer, will continue reporting to President and CEO Dr. Mark Strobeck.
In her new role, Hunter will focus on modernizing infrastructure, implementing operational efficiencies, and aligning execution with strategic priorities to enhance shareholder value and drive sustainable growth. The promotion reflects her successful track record in revitalizing investor relations, corporate communications, and managing IT and transportation functions.
Hunter brings over two decades of experience in organizational renewal, scaling companies, and elevating brands. Previously, she held leadership positions at Venatorx Pharmaceuticals, Safeguard Scientifics, and W.P. Carey. Rockwell Medical is currently positioned as the leading supplier of liquid bicarbonate concentrates and the second-largest supplier of acid and dry bicarbonate concentrates for dialysis patients in the United States.
Rockwell Medical (NASDAQ:RMTI) reported its Q2 2025 financial results, showing significant changes in its business landscape. The company generated $1.8 million in cash flow from operations and maintained a 16% gross margin. Net sales decreased 38% to $16.1 million compared to Q2 2024, primarily due to the transition of their largest customer to another supplier.
The company's cash position strengthened to $18.4 million as of June 30, 2025. Despite challenges, Rockwell secured several new product purchase agreements with major healthcare providers, and currently has over 80% of customers under long-term contracts. The company confirmed its 2025 guidance with expected net sales of $65-70 million and adjusted EBITDA between ($0.5M) to $0.5M.
Rockwell Medical (NASDAQ:RMTI), a global healthcare company specializing in hemodialysis products, has scheduled its Q2 2025 earnings release for August 14, 2025. The company will issue a press release at 6:00 AM ET, followed by a conference call and webcast at 8:00 AM ET.
The earnings call will feature presentations from key executives including CEO Mark Strobeck, CFO Jesse Neri, and Chief Commercial Officer Tim Chole, who will discuss the company's financial and operational results for the quarter ended June 30, 2025. A Q&A session will follow the presentation.
Rockwell Medical (Nasdaq: RMTI) and Innovative Renal Care (IRC) have entered into a three-year partnership agreement for hemodialysis products supply. The multi-million dollar agreement includes supply of liquid and dry acid and bicarbonate hemodialysis concentrates, along with the DAMX45 dry acid concentrate mix system.
The partnership aims to enhance IRC's supply chain continuity and streamline workflows across its U.S. dialysis centers. The agreement includes utilization commitments and an option to extend for an additional year. IRC will benefit from reduced storage requirements while maintaining product quality, utilizing Rockwell's CitraPure® and Dri-Sate® dry acid concentrate powders.
Rockwell Medical (NASDAQ: RMTI) reported Q1 2025 financial results, with net sales of $18.9 million, down 17% from $22.7 million in Q1 2024, primarily due to their largest customer transitioning to another supplier. The company maintained gross profit at $3.0 million, with improved gross margin of 16% vs 14% in Q1 2024. Net loss improved 12% to $1.5 million compared to $1.7 million in Q1 2024.
Cash position decreased to $17.3 million from $21.6 million at year-end 2024. The company confirmed its 2025 guidance with expected net sales of $65-70 million, gross margin of 16-18%, and adjusted EBITDA between ($0.5M) to $0.5M. Notable developments include adding a single-use bicarbonate cartridge to their product portfolio and being named a Great Place to Work® for the third consecutive year.
FAQ
What is the current stock price of Rockwell Med (RMTI)?
What is the market cap of Rockwell Med (RMTI)?
